Our findings identified a novel regulatory mechanism of GSK3β stabilization with PGK1 as a co-chaperone of Hsp90, and emphasized the potential of selecting Hsp90 inhibitors with GSK3β stabilization for more effective cancer treatments. The gene discussed is PGK1; the disease is cancer.